Abstract
Objective: Sorafenib and lenvatinib have been recommended as standard tyrosine kinase inhibitors (TKIs) for progressive radioiodine-refractory differe......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
